Article
EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.
Medical oncology (Northwood, London, England) - 6 Sept 2017
Clay Timothy D, Russell Prudence A, Do Hongdo, Sundararajan Vijaya, Conron Matthew, Wright Gavin M, Solomon Benjamin, Dobrovic Alexander, McLachlan Sue-Anne, Moore Melissa M
Abstract excerpt
Resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) against EGFR mutant lung adenocarcinoma develops after a median of nine to thirteen months. Upregulation of the interleukin-6 (IL-6)/Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway may be a potential source of resistance to EGFR TKIs. We undertook a detailed assessment of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.